Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Clinigen and partner to launch oncology support drug in US

Monday, January 9, 2017 9:25
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Clinigen Group PLC (LON:CLIN) and its partner Cumberland Pharmaceuticals Inc (NASDAQ: CPIX) are to market a second product in the US through their strategic alliance.

Oncology support drug Totect will launch later this year to target the market for cases where anthracycline chemotherapy medication has escaped into the body.

This extravasation can cause severe damage and serious complications, but Totect, which is already FDA approved, can reverse the effect without the need for additional surgery.

Clinigen and Cumberland formed their alliance last year and have already launched one drug, Ethyol.

Arrangements for the launch of Totect are similar with Cumberland to manage all marketing, promotion, and distribution while Clinigen will retain responsibility for manufacturing, regulatory and clinical management of the product.

Clinigen acquired Totect (dexrazoxane hydrochloride) this year as part of its drive in to the US and will continue to market its existing dexrazoxane products, Savene and Cardioxane, everywhere except the US.

Shaun Chilton, Clinigen’s chief executive, said working with Cumberland had allowed it to expand its dexrazoxane portfolio into the sizable US market and would give patients to access a vital emergency support therapy.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.